Cerdelga Seen To Safely, Effectively Treat GD1 After Long-term ERT Use

Cerdelga Seen To Safely, Effectively Treat GD1 After Long-term ERT Use

283182

Cerdelga Seen To Safely, Effectively Treat GD1 After Long-term ERT Use

Cerdelga (eliglustat) safely and effectively treated three adults with Gaucher disease type 1 (GD1), who switched from long-term use of enzyme replacement therapy (ERT) to this substrate reduction therapy (SRT), a study from Korea reports. The study, “One-year experience of oral substrate reduction therapy in three patients with Gaucher disease type I,” was published in the Journal of Genetic Medicine. GD1 is caused by a functional lack of the enzyme beta-glucocerebrosidase. Normally, this enzyme helps to break down…

You must be logged in to read/download the full post.